Welcome to our dedicated page for NeurAxis news (Ticker: $NRXS), a resource for investors and traders seeking the latest updates and insights on NeurAxis stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeurAxis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeurAxis's position in the market.
Rhea-AI Summary
NeurAxis, Inc. (NYSE American: NRXS) has issued a letter to its shareholders detailing significant developments over the past 4 months and the future outlook for the company. The company has achieved strong data publications leading to broad insurance policy coverage and exponential revenue growth. NeurAxis has secured numerous large insurance policy coverages, leading to an increase in revenues. Additionally, the company is anticipating two new revenue opportunities in 2024, including FDA clearance for Functional Dyspepsia for children and an exclusive licensing agreement with the University of Michigan for a chronic constipation device. NeurAxis is confident in surpassing its target of 75M covered lives by the end of 2024 and expects substantial revenue growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
-
Rhea-AI Summary
NeurAxis, Inc. (NRXS) reported Q3 2023 financial results, including a retrospective comparative study on adolescents with functional abdominal pain disorders (FAPD). The study showed that IB-Stim™ therapy was more effective than standard medications in improving abdominal pain and functional disability. The company also announced progress in clinical evidence expansion, exclusive option agreement with the University of Michigan, $3 million in financing, and policy coverage from CareFirst BCBS, among other achievements. Despite a decrease in revenue, the gross margin remained strong at 85.9%. However, the net loss increased to ($4,904.4) thousand, or ($1.35) per common share, compared to the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
-
Rhea-AI Summary
NeurAxis, Inc. (NRXS) announces receipt of policy coverage from CareFirst Blue Cross Blue Shield for the mid-Atlantic region, expanding their covered lives to 8.25 million. This aligns with their strategy to leverage clinical evidence supporting IB-Stim™ and drive market adoption of their technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.17%
Tags
Rhea-AI Summary
NeurAxis, Inc. (NYSE American: NRXS) secures $3 million financing through a preferred stock offering at $2.38 per share. The funding from affiliates of Inspire Health Alliance aims to support sales and marketing efforts for their neuromodulation therapies, including IB-Stim™ technology and the innovative rectal expulsion device (RED). NeurAxis remains engaged with payors to increase coverage of IB-Stim™ and in dialogue with the FDA for additional indications, as well as RED's anticipated 510(k) clearance pathway, targeting commercialization and revenues in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
-
Rhea-AI Summary
NeurAxis, Inc. (NRXS) announces exclusive option agreement with the University of Michigan for innovative rectal expulsion device (RED), targeting chronic constipation market with FDA clearance and commercialization in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
-
Rhea-AI Summary
NeurAxis announces positive results of a comparative study on IB-Stim™ therapy for functional abdominal pain disorders (FAPD) in adolescents, showing improvements in abdominal pain and functional disability compared to standard medications. IB-Stim™ may be a good non-pharmacologic alternative for FAPD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
Rhea-AI Summary
NeurAxis, Inc. reports Q2 2023 financial results and highlights cost-effectiveness of its PENFS or IB-Stim™ therapy in the treatment of irritable bowel syndrome in adolescents. Recent studies show improvements in abdominal pain and disability. Completed IPO raising $6.1 million. Q2 revenue decreased by 5% to $646.0 thousand. Gross profit decreased by 4% to $578.2 thousand. Net loss was ($2,235.6) thousand.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
-
Rhea-AI Summary
NeurAxis to present at Gilmartin Group Emerging Growth Showcase on September 21, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.87%
Tags
-
Rhea-AI Summary
NeurAxis announces positive results from a study on IB-Stim™ therapy in children with pain related disorders, showing significant reductions in symptoms and improvements in quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.92%
Tags
Rhea-AI Summary
NeurAxis highlights a study on the efficacy of its neuromodulation therapy for post-concussion syndrome in children. Positive results could lead to FDA clearance and a groundbreaking therapeutic option. The company aims to expand pediatric indications for its technology, targeting a $2 billion market. Currently enrolling up to 100 patients in a clinical trial at Children’s Hospital of Orange County, CA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
NeurAxis, Inc.
NYSE:NRXS
NRXS Rankings
NRXS Stock Data
20.05M
1.91M
47.47%
1.53%
0.13%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
CARMEL